Inmune Bio Inc.
corporate_fare Company Profile
Inmune Bio Inc. (NASDAQ:INMB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 32 items for INMB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for INMB spans 424B5, 8-K, 10-Q.
Recent high-impact activity:
- INmune Bio Trims Q3 Loss to $4.7M, Sets Full UK Filing for February 2027
- Inmune Bio Prices $4.5M Stock Sale at $1.50 With Matching Warrant Package
- $4.5M Direct Offering Priced at $1.50 a Share, 6% Below Market
- Inmune Bio Signs Uniphar Commercial Pact, Pulls UK MAA Filing Forward to Feb 2027
- Ebstrocel UK Filing Accelerated to Feb 2027, Approval Targeted Mid-2027
Financial Snapshot
Short Interest & Short Volume
14.40 days to coverFINRA reported short interest of 2,658,847 shares in INMB as of the October 30, 2026 settlement, a 7.9% decrease from the prior period — about 14.4 days to cover at its recent average daily volume. On November 20, 2026, 43.1% of INMB volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for INMB, detected from its recent SEC filings · based on capital-structure filings through 2026-10-29.
Priced $4.5M Stock and Warrant Deal · Net Proceeds About $4.0 Million
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →